InvestorsObserver is giving HTG Molecular Diagnostics (HTGM) an Analyst Rating Rank of 67, meaning HTGM is ranked higher by analysts than 67% of stocks. The average projection by analysts for HTGM is $1.125 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With HTG Molecular Diagnostics Stock Today?
HTG Molecular Diagnostics (HTGM) stock has fallen -2.42% while the S&P 500 is up 0.52% as of 11:08 AM on Monday, Nov 23. HTGM is lower by -$0.10 from the previous closing price of $4.27 on volume of 316,646 shares. Over the past year the S&P 500 has gained 14.11% while HTGM is lower by -56.56%. HTGM lost -$0.32 per share the over the last 12 months.